Prostamax is a short synthetic tetrapeptide—Lys‑Glu‑Asp‑Pro (KEDP)—studied as a peptide bioregulator for its capacity to modulate chromatin structure and gene expression, particularly in immune cells and prostate-related models. It’s not an approved therapy; it is a research compound used under laboratory conditions only.